See also

References

1. ^Gilling K, Jatzke C, Wollenburg C, Vanejevs M, Kauss V, Jirgensons A, Parsons CG (2007). "A novel class of amino-alkylcyclohexanes as uncompetitive, fast, voltage-dependent, N-methyl-D-aspartate (NMDA) receptor antagonists--in vitro characterization".Journal of Neural Transmission.114 (12):1529–37.doi:10.1007/s00702-007-0792-7.PMID 17728997.S2CID 8654883.
2. ^Danysz W, Parsons CG, Jirgensons A, Kauss V, Tillner J (2002). "Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists".Current Pharmaceutical Design.8 (10):835–43.doi:10.2174/1381612024607117.PMID 11945134.
3. ^Danysz W, Parsons CG (March 2002). "Neuroprotective potential of ionotropic glutamate receptor antagonists".Neurotoxicity Research.4 (2):119–26.doi:10.1080/10298420290015872.PMID 12829411.S2CID 9413469.
4. ^Clinical trial numberNCT00405886 for "Neramexane for Tinnitus" atClinicalTrials.gov
5. ^Clinical trial numberNCT00739635 for "Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus" atClinicalTrials.gov
6. ^Rammes G, Schierloh A (February 2006). "Neramexane (merz pharmaceuticals/forest laboratories)".IDrugs.9 (2):128–35.PMID 16523403.
7. ^Kotlinska J, Biala G, Rafalski P, Bochenski M, Danysz W (October 2004). "Effect of neramexane on ethanol dependence and reinforcement".European Journal of Pharmacology.503 (1–3):95–8.doi:10.1016/j.ejphar.2004.09.036.PMID 15496302.
8. ^Klein T, Magerl W, Hanschmann A, Althaus M, Treede RD (January 2008). "Antihyperalgesic and analgesic properties of the N-methyl-D-aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic hyperalgesia".European Journal of Pain.12 (1):17–29.doi:10.1016/j.ejpain.2007.02.002.PMID 17449306.S2CID 2875679.
9. ^Kos T, Legutko B, Danysz W, Samoriski G, Popik P (September 2006). "Enhancement of antidepressant-like effects but not brain-derived neurotrophic factor mRNA expression by the novel N-methyl-D-aspartate receptor antagonist neramexane in mice".The Journal of Pharmacology and Experimental Therapeutics.318 (3):1128–36.doi:10.1124/jpet.106.103697.PMID 16740621.S2CID 11450694.
10. ^Zoladz PR, Campbell AM, Park CR, Schaefer D, Danysz W, Diamond DM (October 2006). "Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane".Pharmacology, Biochemistry, and Behavior.85 (2):298–306.doi:10.1016/j.pbb.2006.08.011.PMID 17045636.S2CID 9614195.
11. ^Plazas PV, Savino J, Kracun S, Gomez-Casati ME, Katz E, Parsons CG, et al. (July 2007). "Inhibition of the alpha9alpha10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-D-aspartate receptors".European Journal of Pharmacology.566 (1–3):11–9.doi:10.1016/j.ejphar.2007.03.026.hdl:11336/79674.PMID 17466293.
12. ^Suckfüll M, Althaus M, Ellers-Lenz B, Gebauer A, Görtelmeyer R, Jastreboff PJ, et al. (January 2011)."A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus".BMC Ear, Nose and Throat Disorders.11: 1.doi:10.1186/1472-6815-11-1.PMC 3031239.PMID 21223542.